Drug Profile


Alternative Names: IPI 1040; PF-1228305; Sitaxsentan; Sitaxsentan sodium; TBC 11251; Thelin

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Pfizer
  • Class Antihypertensives; Benzodioxoles; Heart failure therapies; Isoxazoles; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension

Highest Development Phases

  • Market Withdrawal Pulmonary arterial hypertension
  • Discontinued Heart failure; Kidney disorders

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 10 Dec 2010 Discontinued - Phase-II for Kidney disorders in United Kingdom (PO)
  • 10 Dec 2010 Discontinued - Phase-III for Pulmonary hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top